IBDEI1HA ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23639,0)
 ;;=F16.11^^105^1179^1
 ;;^UTILITY(U,$J,358.3,23639,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23639,1,3,0)
 ;;=3^Hallucinogen Abuse,In Remission
 ;;^UTILITY(U,$J,358.3,23639,1,4,0)
 ;;=4^F16.11
 ;;^UTILITY(U,$J,358.3,23639,2)
 ;;=^268239
 ;;^UTILITY(U,$J,358.3,23640,0)
 ;;=F18.10^^105^1180^2
 ;;^UTILITY(U,$J,358.3,23640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23640,1,3,0)
 ;;=3^Inhalant Use Disorder,Mild
 ;;^UTILITY(U,$J,358.3,23640,1,4,0)
 ;;=4^F18.10
 ;;^UTILITY(U,$J,358.3,23640,2)
 ;;=^5003380
 ;;^UTILITY(U,$J,358.3,23641,0)
 ;;=F18.20^^105^1180^3
 ;;^UTILITY(U,$J,358.3,23641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23641,1,3,0)
 ;;=3^Inhalant Use Disorder,Moderate-Severe
 ;;^UTILITY(U,$J,358.3,23641,1,4,0)
 ;;=4^F18.20
 ;;^UTILITY(U,$J,358.3,23641,2)
 ;;=^5003392
 ;;^UTILITY(U,$J,358.3,23642,0)
 ;;=F18.21^^105^1180^4
 ;;^UTILITY(U,$J,358.3,23642,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23642,1,3,0)
 ;;=3^Inhalant Use Disorder,Moderate-Severe,In Remission
 ;;^UTILITY(U,$J,358.3,23642,1,4,0)
 ;;=4^F18.21
 ;;^UTILITY(U,$J,358.3,23642,2)
 ;;=^5003393
 ;;^UTILITY(U,$J,358.3,23643,0)
 ;;=F18.14^^105^1180^5
 ;;^UTILITY(U,$J,358.3,23643,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23643,1,3,0)
 ;;=3^Inhalant-Induced Depressive Disorder w/ Mild Use Disorder
 ;;^UTILITY(U,$J,358.3,23643,1,4,0)
 ;;=4^F18.14
 ;;^UTILITY(U,$J,358.3,23643,2)
 ;;=^5003384
 ;;^UTILITY(U,$J,358.3,23644,0)
 ;;=F18.24^^105^1180^6
 ;;^UTILITY(U,$J,358.3,23644,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23644,1,3,0)
 ;;=3^Inhalant-Induced Depressive Disorder w/ Moderate to Severe Use Disorder
 ;;^UTILITY(U,$J,358.3,23644,1,4,0)
 ;;=4^F18.24
 ;;^UTILITY(U,$J,358.3,23644,2)
 ;;=^5003397
 ;;^UTILITY(U,$J,358.3,23645,0)
 ;;=F18.11^^105^1180^1
 ;;^UTILITY(U,$J,358.3,23645,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23645,1,3,0)
 ;;=3^Inhalant Abuse,In Remission
 ;;^UTILITY(U,$J,358.3,23645,1,4,0)
 ;;=4^F18.11
 ;;^UTILITY(U,$J,358.3,23645,2)
 ;;=^5151305
 ;;^UTILITY(U,$J,358.3,23646,0)
 ;;=F11.10^^105^1181^5
 ;;^UTILITY(U,$J,358.3,23646,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23646,1,3,0)
 ;;=3^Opioid Use Disorder,Mild
 ;;^UTILITY(U,$J,358.3,23646,1,4,0)
 ;;=4^F11.10
 ;;^UTILITY(U,$J,358.3,23646,2)
 ;;=^5003114
 ;;^UTILITY(U,$J,358.3,23647,0)
 ;;=F11.129^^105^1181^4
 ;;^UTILITY(U,$J,358.3,23647,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23647,1,3,0)
 ;;=3^Opioid Intoxication w/o Perceptual Disturbances;Mild Use Disorder
 ;;^UTILITY(U,$J,358.3,23647,1,4,0)
 ;;=4^F11.129
 ;;^UTILITY(U,$J,358.3,23647,2)
 ;;=^5003118
 ;;^UTILITY(U,$J,358.3,23648,0)
 ;;=F11.14^^105^1181^9
 ;;^UTILITY(U,$J,358.3,23648,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23648,1,3,0)
 ;;=3^Opioid-Induced Depressive Disorder w/ Mild Use Disorder
 ;;^UTILITY(U,$J,358.3,23648,1,4,0)
 ;;=4^F11.14
 ;;^UTILITY(U,$J,358.3,23648,2)
 ;;=^5003119
 ;;^UTILITY(U,$J,358.3,23649,0)
 ;;=F11.182^^105^1181^11
 ;;^UTILITY(U,$J,358.3,23649,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23649,1,3,0)
 ;;=3^Opioid-Induced Sleep Disorder w/ Mild Use Disorder
 ;;^UTILITY(U,$J,358.3,23649,1,4,0)
 ;;=4^F11.182
 ;;^UTILITY(U,$J,358.3,23649,2)
 ;;=^5003124
 ;;^UTILITY(U,$J,358.3,23650,0)
 ;;=F11.20^^105^1181^6
 ;;^UTILITY(U,$J,358.3,23650,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23650,1,3,0)
 ;;=3^Opioid Use Disorder,Moderate-Severe
 ;;^UTILITY(U,$J,358.3,23650,1,4,0)
 ;;=4^F11.20
